4-Hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in lung, lower esophagus and cardia of sudden death victims

Toxicology

Volumn 245, Issue 1-2, 2008, Pages 154-161

  Schlöbe, Daniela ^a   Hölzle, Daniel ^a   Hatz, Dorothea ^a,b   von Meyer, Ludwig ^a   Tricker, Anthony R ^c   Richter, Elmar ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Philip Morris Products SA   (Switzerland)

Author keywords

Cardia; DNA adducts; Esophagus; Lung; Smoking; Sudden death victim; Tobacco specific nitrosamines

Indexed keywords

4 HYDROXY 1 (3 PYRIDYL) 1 BUTANONE; ALKANONE; ANION; COTININE; NITROSONORNICOTINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOPSY; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA ADDUCT; ESOPHAGUS; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IONIZATION; LUNG; LUNG CANCER; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SUDDEN DEATH;

BIOLOGICAL MARKERS; BUTANONES; CARDIA; COTININE; DEATH, SUDDEN; DNA ADDUCTS; ESOPHAGUS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PYRIDINES; SENSITIVITY AND SPECIFICITY; SMOKING;

NICOTIANA TABACUM;

EID: 39249085060     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.12.021     Document Type: Article

References (67)

1. Anderson L.A., Watson R.G.P., Murphy S.J., Johnston B.T., Comber H., Mc Guigan J., Reynolds J.V., and Murray L.J. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J. Gastroenterol. 13 (2007) 1585-1594
2. Atawodi S.E., Lea S., Nyberg F., Mukeria A., Constantinescu V., Ahrens W., Brueske-Hohlfeld I., Fortes C., Boffetta P., and Friesen M.D. 4-Hydroxy-1-(3-pyridyl)-1-butanone-hemoglobin adducts as biomarkers of exposure to tobacco smoke: validation of a method to be used in multicenter studies. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 817-821
3. Awan A.K., Iftikhar S.Y., Morris T.M., Clarke P.A., Grabowska A.M., Waraich N., and Watson S.A. Androgen receptors may act in a paracrine manner to regulate oesophageal adenocarcinoma growth. EJSO 33 (2007) 561-568
4. Becker N., Muscat J.E., and Wynder E.L. Cancer mortality in the United States and Germany. J. Cancer Res. Clin. Oncol. 127 (2001) 293-300
5. Belinsky S.A., Devereux T.R., White C.M., Foley J.F., Maronpot R.R., and Anderson M.W. Role of Clara cells and type II cells in the development of pulmonary tumors in rats and mice following exposure to a tobacco-specific nitrosamine. Exp. Lung Res. 17 (1991) 263-278
6. Bollschweiler E., Wolfgarten E., Gutschow C., and Hölscher A.H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92 (2001) 549-555
7. Branner B., Kutzer C., Zwickenpflug W., Scherer G., Heller W.D., and Richter E. Haemoglobin adducts from aromatic amines and tobacco-specific nitrosamines in pregnant smoking and nonsmoking women. Biomarkers 3 (1998) 35-47
8. Carmella S.G., Kagan S.S., Kagan M., Foiles P.G., Palladino G., Quart A.M., Quart E., and Hecht S.S. Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff-dippers, smokers, and non-smokers. Cancer Res. 50 (1990) 5438-5445
9. Carmella S.G., Akerkar S., and Hecht S.S. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. Cancer Res. 53 (1993) 721-724
10. CDC, 2007. Centers for Disease Control and Prevention, Department of Health and Human Services: percentage of adults who were current, former, or never smokers, overall and by sex, race, Hispanic origin, age, education, and poverty status: National Health Interview. http://www.cdc.gov/tobacco/research_data/adults_prev/prevali.htm, accessed August 7, 2007.
11. Chen X., Yang G.-Y., Ding W.Y., Bondoc F., Curtis S.K., and Yang C.S. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 20 (1999) 1801-1807
12. Combet E., Paterson S., Iijima K., Winter J., Mullen W., Crozier A., Preston T., and McColl K.E.L. Fat transforms ascorbic acid from inhibiting to promoting acid catalysed N-nitrosation. Gut 56 (2007) 1678-1684
13. Corley D.A., and Buffler P.A. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. Int. J. Epidemiol. 30 (2001) 1415-1425
14. Corley D.A., Kubo A., and Zhao W. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut 56 (2007) 756-762
15. Devesa S.S., Blot W.J., and Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
16. Falter B., Kutzer C., and Richter E. Biomonitoring of hemoglobin adducts: aromatic amines and tobacco-specific nitrosamines. Clin. Invest. 72 (1994) 364-371
17. Foiles P.G., Akerkar S.A., Carmella S.G., Kagan M., Stoner G.D., Resau J.H., and Hecht S.S. Mass spectrometric analysis of tobacco-specific nitrosamine DNA-adducts in smokers and nonsmokers. Chem. Res. Toxicol. 4 (1991) 364-368
18. Haglund J., Henderson A.P., Golding B.T., and Törnqvist M. Evidence for phosphate adducts in DNA from mice treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Chem. Res. Toxicol. 15 (2002) 773-779
19. Hampel H., Abraham N.S., and El Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann. Intern. Med. 143 (2005) 199-211
20. Hashimoto K., Ohsawa K.-I., and Kimura M. Mutations induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in the lacZ and cII genes of Muta™ Mouse. Mutat. Res. 560 (2004) 119-131
21. Hecht S.S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11 (1998) 559-603
22. Hecht S.S. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res. 424 (1999) 127-142
23. Hecht S.S. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 23 (2002) 907-922
24. Hecht S.S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer 3 (2003) 733-744
25. Hecht S.S. A biomarker of exposure to environmental tobacco smoke (ETS) and Ernst Wynder's opinion about ETS and lung cancer. Prev. Med. 43 (2006) 256-260
26. 2-substituted pyrimidine adducts formed in reactions of 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanol with DNA. Chem. Res. Toxicol. 17 (2004) 588-597
27. Hecht S.S., Han S., Kenney P.M., Wang M., Lindgren B., Wang Y., Lao Y., Hochalter J.B., and Upadhyaya P. Investigation of the reaction of myosmine with sodium nitrite in vitro and in rats. Chem. Res. Toxicol. 20 (2007) 543-549
28. Herzog C.R., Desai D., and Amin S. Array CGH analysis reveals chromosomal aberrations in mouse lung adenocarcinomas induced by the human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Biochem. Biophys. Res. Commun. 341 (2006) 856-863
29. Hoffmann D., Hoffmann I., and El-Bayoumy K. The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem. Res. Toxicol. 14 (2001) 767-790
30. Hölzle D., Schlöbe D., Tricker A.R., and Richter E. Mass spectrometric analysis of 4-hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in human lung. Toxicology 232 (2007) 277-285
31. Hukkanen J., Jacob P., and Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57 (2005) 79-115
32. International Agency for Research on Cancer. Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans vol. 83 (2004), IARC, Lyon, France pp. 1-1452
33. International Agency for Research on Cancer, 2007. Smokeless tobacco and tobacco-specific nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. vol. 89, IARC, Lyon, France, pp. 1-626.
34. Kubo A., and Corley D.A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 872-878
35. Lagergren J., Bergström R., Lindgren A., and Nyrén O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int. J. Cancer 85 (2000) 340-346
36. Lao Y., Yu N., Kassie F., Villalta P.W., and Hecht S.S. Analysis of pyridyloxobutyl DNA adducts in F344 rats chronically treated with (R)- and (S)-N′-nitrosonornicotine. Chem. Res. Toxicol. 20 (2007) 246-256
37. Lao Y., Yu N., Kassie F., Villalta P.W., and Hecht S.S. Formation and accumulation of pyridyloxobutyl DNA adducts in F344 rats chronically treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem. Res. Toxicol. 20 (2007) 235-245
38. Lepage C., Bouvier A.-M., Manfredi S., Coatmeur O., Cheynel N., and Faivre J. Trends in incidence and management of esophageal adenocarcinoma in a well-defined population. Gastroenterol. Clin. Biol. 29 (2005) 1258-1263
39. Levi F., Lucchini F., Negri E., Boyle P., and La Vecchia C. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int. J. Cancer 110 (2004) 155-169
40. Maier M., Schulze A., and Richter E. Biomonitoring of myosmine in human milk and saliva. Toxicol. Lett. 158 (2005) S201-S202
41. Meger M., Meger-Kossien I., Riedel K., and Scherer G. Biomonitoring of environmental tobacco smoke (ETS)-related exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Biomarkers 5 (2000) 33-45
42. 6-Pyridyloxobutylguanine adducts contribute to the mutagenic properties of pyridyloxobutylating agents. Chem. Res. Toxicol. 18 (2005) 1619-1625
43. Moyer T.P., Charlson J.R., Enger R.J., Dale L.C., Ebbert J.O., Schroeder D.R., and Hurt R.D. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin. Chem. 48 (2002) 1460-1471
44. Newnham A., Quinn M.J., Babb P., Kang J.Y., and Majeed A. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-1998. Aliment. Pharmacol. Ther. 17 (2003) 665-676
45. 6-[4-oxo-4-(3-pyridyl)butyl]guanine in Escherichia coli and human cells. Chem. Res. Toxicol. 15 (2002) 165-169
46. Peto R., Darby S., Deo H., Silcocks P., Whitley E., and Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br. Med. J. 321 (2000) 323-329
47. Phillips D.H. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 23 (2002) 1979-2004
48. 32P-postlabeling assay for aromatic carcinogen-DNA adducts. Method Toxicol. 1B (1994) 201-215
49. Ryan A.M., Rowley S.P., Fitzgerald A.P., Ravi N., and Reynolds J.V. Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity. Eur. J. Cancer 42 (2006) 1151-1158
50. Samanic C., Chow W.-H., Gridley G., Jarvholm B., and Fraumeni J.F. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17 (2006) 901-909
51. Sihvo E.I.T., Salminen J.T., Rantanen T.K., Rämö O.J., Ahotupa M., Färkkilä M., Auvinen M.I., and Salo J.A. Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int. J. Cancer 102 (2002) 551-555
52. Skarping G., Willers S., and Dalene M. Determination of cotinine in urine using glass capillary gas chromatography and selective detection, with special reference to the biological monitoring of passive smoking. J. Chromatogr. 454 (1988) 293-301
53. Smith C.J., Perfetti T.A., Garg R., and Hansch C. IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. Food Chem. Toxicol. 41 (2003) 807-817
54. Smith K.J., O'Brien S.M., Smithers B.M., Gotley D.C., Webb P.M., Green A.C., and Whiteman D.C. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2481-2486
55. Suzuki H., Iijima K., Moriya A., McElroy K., Scobie G., Fyfe V., and McColl K.E.L. Conditions for acid catalysed luminal nitrosation are maximal at the gastric cardia. Gut 52 (2003) 1095-1101
56. Suzuki H., Iijima K., Scobie G., Fyfe V., and McColl K.E.L. Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. Gut 54 (2005) 1527-1535
57. Tricker A.R. Biomarkers derived from nicotine and its metabolites: a review. Beitr. Tabakforsch. Int. 22 (2006) 147-175
58. Tyroller S., Zwickenpflug W., and Richter E. New sources of dietary myosmine uptake from cereals, fruits, vegetables and milk. J. Agric. Food Chem. 50 (2002) 4909-4915
59. van Blankenstein M., Looman C.W.N., Siersema P.D., Kuipers E.J., and Coebergh J.W.W. Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003. Br. J. Cancer 96 (2007) 1767-1771
60. 6-alkylguanine-DNA alkyltransferase. Chem. Res. Toxicol. 10 (1997) 562-567
61. Wang M., Cheng G., Sturla S.J., Shi Y., McIntee E.J., Villalta P.W., Upadhyaya P., and Hecht S.S. Identification of adducts formed by pyridyloxobutylation of deoxyguanosine and DNA by 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone, a chemically activated form of tobacco specific carcinogens. Chem. Res. Toxicol. 16 (2003) 616-626
62. Weitkunat R., Sanders E., and Lee P.N. Meta-analysis of the relation between European and American smokeless tobacco and oral cancer. BMC Public Health 7 (2007) 334
63. Wilp J., Zwickenpflug W., and Richter E. Nitrosation of dietary myosmine as risk factor of human cancer. Food Chem. Toxicol. 40 (2002) 1223-1228
64. 6-pyridyloxobutylation by the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Biochemistry 43 (2004) 540-549
65. Zwickenpflug W. N-nitrosation of myosmine yields HPB (4-hydroxy-1-(3-pyridyl)-1-butanone) and NNN (N-nitrosonornicotine). J. Agric. Food Chem. 48 (2000) 392-394
66. Zwickenpflug W., and Tyroller S. Reaction of the tobacco alkaloid myosmine with hydrogen peroxide. Chem. Res. Toxicol. 19 (2006) 150-155
67. Zwickenpflug W., Meger M., and Richter E. Occurrence of the tobacco alkaloid myosmine in nuts and nut products of Arachus hypogaea and Corylus avellana. J. Agric. Food Chem. 46 (1998) 2703-2706